Oncomed

About

Oncomed Pharmaceuticals, Inc. is a biopharmaceutical company that is developing drugs based on the newly discovered concept of 'cancer stem cells'. The company's scientific founders were among those responsible for first isolating such cancer stem cells, which appear to be the rare cells in tumors responsible for producing malignancy and tumor growth. In 2007 OncoMed and GlaxoSmithKline (“GSK”) formed a strategic alliance to develop cancer therapeutics based on the Company's cancer stem cell antibody technology. In 2010, Oncomed completed a second major collaboration partnership with Bayer Pharmaceuticals for development of antibodies in the Wnt pathway. The company retains rights to many additional drug development candidates and has the capital in place to finance the completion of thirteen major phase ll clinical trials by the end of 2016.